IN THE NEWS TODAY
Moderna (MRNA) said its Covid vaccine was 96% effective in kids ages 12 to 17, according to early data released Thursday along with the company s mixed first-quarter earnings and revenue. Shares fell more than 9% in the premarket. (CNBC)
Citing early data from another ongoing trial, Moderna said Wednesday a Covid booster shot generated a promising immune response against variants first identified in South Africa and Brazil. U.S. health officials said earlier Wednesday that highly contagious variants remain a wild card heading into the summer. (CNBC)
The Biden administration said Wednesday it supports waiving intellectual property protections for Covid vaccines, as other countries around the world struggle to manufacture the life-saving doses. Pfizer CEO Albert Bourla on CNBC on Tuesday that such a move would not impact the production of its Covid vaccine.
Novartis biosimilar targets rivals Eylea eye treatment
leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.
Up 6% Last Week Can Regeneron Pharmaceuticals Stock Rise Further?
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Roche’s faricimab hits primary endpoint in wet AMD studies
26th January 2021
Roche’s investigational bispecific antibody faricimab has hit the primary endpoint in two Phase III studies in people living with neovascular or wet age-related macular degeneration (nAMD).
In the identically designed studies – TENAYA and LUCERNE – faricimab, administered via injections at fixed intervals, met the primary endpoint, showing that people receiving the treatment achieved visual acuity outcomes that were non-inferior to those receiving Regeneron’s Eylea (aflibercept) injections every eight weeks.
Within both studies, nearly half (45%) of participants were treated with faricimab every 16 weeks during the first year.
“These results show the potential of faricimab as a new class of medicine that could extend time between treatments for people living with neovascular age-related macular degeneration,” said Levi Garraway, chief medical officer and head of Global Product Development,